All In Biotech

Drug Trial Radar · NCT05145127

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF MARSTACIMAB PROPHYLAXIS IN SEVERE (COAGULATION FACTOR ACTIVITY <1%) HEMOPHILIA A PARTICIPANTS WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY ≤2%) WITH OR WITHOUT INHIBITORS

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

245

Planned (sponsor's estimate)

Start

Nov 17, 2021

Primary completion

Jul 31, 2030

Study completion Jul 31, 2030

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 1 year, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005 and from the Phase 3 Study B7841008. Study B7841005: approximately 145 adolescent and adult participants 12 to \<75 years of age with severe hemophilia A or moderately severe to severe hemophilia B (defined as FVIII activity \<1% or FIX activity ≤2%, respectively) with or without inhibitors are expected to be enrolled in Study B7841005 during which they will receive prophylaxis (defined as treatment by SC injection of marstacimab). Study B7841008: this is an ongoing Phase 3, open-label study in pediatric participants \<18 years of age with severe hemophilia A (FVIII Coagulation Factor Activity \<1%) or moderately severe to severe hemophilia B (FIX Coagulation Factor Activity ≤2%). A sequential approach will be used in enrolling at least 100 pediatric participants, at least 20 of which will be aged ≥12 to \<18 years and at least 80 participants will be aged ≥1 to \<12 years. At the start of study B7841008, the dosing and data available in adolescent and adult participants in Study B7841005 supported the initiation of B7841008 study in participants aged ≥12 to \<18 years. Subsequently, additional safety and efficacy data from adolescent participants in Study B7841005 became available for benefit/risk assessment in support of dosing participants aged ≥6 to \<12 years. Based on the positive benefit/risk assessment conducted by both internal Pfizer review and eDMC review, dosing of the ≥6 to \<12 years age group was initiated in June 2023 in B7841008 Study. Data from participants ≥6 years from B7841008 Study and Study B7841005 will support the dosing of participants aged ≥1 to \<6 years. All participants will be provided the prefilled pen (PFP) for administration of marstacimab in the study. Use of the prefilled syringe (PFS) will be permitted at the investigator's discretion for those participants who have difficulty with administration of the PFP. Additionally, participants will be provided the PFS for use in this study in countries where the PFS is anticipated to be the only presentation available commercially. An optional, open-label, single arm, substudy using the PFP was completed in the first 23 participants rolled over from Study B7841005 who agreed to participate in the substudy.

Conditions

  • Hemophilia A
  • Hemophilia B

Interventions

  • PF-06741086Drug

    For participants aged ≥12 years 300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria. For participants aged ≥6 to \<12 years is marstacimab 150 mg SC for initial loading dose followed by 75 mg SC QW. 150 mg sc qw is prescribed for participants who meet dose escalation criteria.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subject reporting Adverse EventsTime frame: Baseline up to 7 years
  2. Number of subjects reporting Serious Adverse EventsTime frame: Baseline up to 7 years
  3. Incidence and severity of thrombotic eventsTime frame: Baseline up to 7 years
  4. Incidence and severity of thrombotic microangiopathyTime frame: Baseline up to 7 years
  5. Number of subjects reporting Disseminated intravascular coagulalopathy/consumption coagulopathyTime frame: Baseline up to 7 years
  6. Incidence of clinically significant persistent NAb against marstacimabTime frame: Baseline up to 7 years
  7. Incidence and severity of injection site reactionTime frame: Baseline up to 7 years
  8. Clinically significant changes in vital signs from baselineTime frame: Baseline up to 7 years
  9. Incidence of clinically significant laboratory value abnormalitiesTime frame: Baseline up to 7 years
  10. Incidence of severe hypersensitivity and anaphylactic reactionsTime frame: Baseline up to 7 years

Locations

78 sites in 24 countries. Site status is shown where the registry gives one.

  • University of Iowa

    Iowa City, Iowa · Active not recruiting

  • Northwell Health HTC

    New Hyde Park, New York · Recruiting

  • The Feinstein Institutes for Medical Research

    Philadelphia, Pennsylvania · Recruiting

  • Washington Institute for Coagulation d/b/a WACBD

    Seattle, Washington · Recruiting

  • Arbesu Hematología

    Mendoza, Argentina · Recruiting

  • Royal Children's Hospital

    Melbourne, Victoria, Australia · Recruiting

  • HEMOES

    Vitória, Espírito Santo, Brazil · Recruiting

  • Stollery Children's Hospital

    Edmonton, Alberta, Canada · Recruiting

  • Hamilton Health Sciences - McMaster University Medical Centre

    Hamilton, Ontario, Canada · Recruiting

  • Hamilton Health Sciences - McMaster University Medical Centre

    Hamilton, Ontario, Canada · Recruiting

  • Beijing Children's Hospital, Capital Medical University

    Beijing, China · Recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • The Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Recruiting

  • Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Institute of hematology&blood disease hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Klinicki bolnicki centar Zagreb

    Zagreb, Croatia · Recruiting

  • Aarhus Universitetshospital, Skejby

    Aarhus, Central Jutland, Denmark · Recruiting

  • Hôpital Universitaire Necker Enfants Malades

    Paris, France · Recruiting

  • The University of Hong Kong (HKU)-Queen Mary Hospital (QMH)

    Hong Kong, Hong Kong · Recruiting

  • Prince of Wales Hospital

    Hong Kong, Hong Kong · Recruiting

  • Queen Mary Hospital

    Hong Kong, Hong Kong · Recruiting

  • The Chinese University of Hong Kong

    Ma Liu Shui, Hong Kong · Recruiting

  • Nirmal Hospital Pvt Ltd.

    Surat, Gjuarat, India · Recruiting

  • K.J Somaiya Hospital & Research Centre, Somaiya Ayurvihar Complex

    Mumbai, Maharashtra, India · Recruiting

  • Sahyadri Super Speciality Hospital

    Pune, Maharashtra, India · Recruiting

  • Nil Ratan Sircar Medical College and Hospital

    Kolkata, West Bengal, India · Recruiting

  • Sheba Medical Center

    Ramat Gan, Central District, Israel · Recruiting

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Italy · Recruiting

  • IRCCS Istituto Giannina Gaslini

    Genoa, Liguria, Italy · Recruiting

  • Istituto Clinico Humanitas

    Rozzano, Milano, Italy · Recruiting

  • AOU Policlinico Umberto I

    Roma, RM, Italy · Recruiting

  • Hiroshima University Hospital

    Hiroshima, Japan · Active not recruiting

  • Saga University Hospital

    Saga, Japan · Recruiting

  • Nagoya University Hospital - Transfusion Medicine

    Nagoya, Aichi-ken, Japan · Active not recruiting

  • Nagano Children's Hospital

    Azumino, Nagano, Japan · Recruiting

  • Nara Medical University Hospital

    Kashihara, Nara, Japan · Recruiting

  • Saitama Medical University Hospital

    Lruma-gun, Saitama, Japan · Recruiting

  • Saitama Children's Medical Center

    Saitama-shi, Saitama, Japan · Recruiting

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.